Michael Dickinson

Treatment approaches for patients with TP53-mutated mantle cell lymphoma.

Thomas E Lew, Adrian Minson, Michael Dickinson, Sasanka M Handunnetti, Piers Blombery, Amit Khot, Mary Ann Anderson, David Ritchie, Constantine S Tam, John F Seymour

Journal article  |  2023  |  Lancet Haematol

Mantle cell lymphoma is an uncommon subtype of lymphoma characterised by clinical and biological heterogeneity. Although most pati..

Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.

Nathan Hale Fowler, Michael Dickinson, Monalisa Ghosh, Andy I Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Etienne Jousseaume, Catherine Thieblemont, Martin Dreyling, Stephen J Schuster

Journal article  |  2023  |  Transplant Cell Ther

Follicular lymphoma (FL) is generally considered an indolent disease, although patients with relapsing FL experience progressively..

Clinical characteristics of Australian treatment-naive patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

James Nguyen, Cameron Wellard, Eliza Chung, Chan Y Cheah, Michael Dickinson, Nicole Wong Doo, Colm Keane, Dipti Talaulikar, Leanne Berkahn, Susan Morgan, Nada Hamad, Tara Cochrane, Anna M Johnston, Cecily Forsyth, Stephen Opat, Allison Barraclough, Howard Mutsando, Sumita Ratnasingam, Pratyush Giri, Erica M Wood, et al.

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been syste..

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Michael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wróbel, Fritz Offner, Marek Trněný, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Mark Dixon, Emma Clark, Kathryn Humphrey, et al.

Journal article  |  2022  |  N Engl J Med

BACKGROUND: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a ..

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.

Gilles Salles, Stephen J Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers EM Patten, Bastian von Tresckow, Sonali M Smith, Ana Jiménez-Ubieto, Keith L Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, Brian K Link

Journal article  |  2022  |  Blood Adv

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relap..

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Mary Ann Anderson, Leanne Berkahn, Chan Cheah, Michael Dickinson, Maher K Gandhi, Pratyush Giri, Eliza A Hawkes, Anna Johnston, Colm Keane, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Dipti Talaulikar, Judith Trotman, Janne Williams, Erica M Wood, Tasman Armytage, Allison Barraclough, Duncan Carradice, Geoffrey Chong, et al.

Journal article  |  2022  |  BMC MEDICAL RESEARCH METHODOLOGY

BACKGROUND: Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to ..

EXABS-198-ABCL Bispecific Antibodies for Aggressive B-Cell Lymphoma.

Rory Bennett, Michael Dickinson

Journal article  |  2022  |  Clin Lymphoma Myeloma Leuk

Treatment of Mantle-Cell Lymphoma

Edward RS Cliff, Michael Dickinson

Journal article  |  2022  |  NEW ENGLAND JOURNAL OF MEDICINE

Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy

Constantine S Tam, PJ Ho, Duncan Purtill, Emily Blyth, Jason Butler, Michael Dickinson, Simon Harrison

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Joel Wight, Nada Hamad, Belinda A Campbell, Matthew Ku, Kenneth Lee, Hannah Rose, Tasman Armytage, Maya Latimer, Hui-Peng Lee, Sze-Ting Lee, Michael Dickinson, Richard Khor, Emma Verner

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although a..